Search
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalLenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDifluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnDifluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersNorgestrel
go.drugbank.com/drugs/DB09389ApprovedNorgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only t...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigationalIxazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center, it is considered a boronate proteasome inhibitor. More than 99% of the drug compound is the R-enantiomer. Ixazomib was a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOleandomycin
go.drugbank.com/drugs/DB11442ExperimentalVet approvedOleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSarafloxacin
go.drugbank.com/drugs/DB11491ApprovedVet approvedWithdrawnSarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTreosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigationalTreosulfan is a prodrug alternative to busulfan for myeloablative conditioning prior to hematopoietic stem cell transplantation. It was approved by the EMA in June 2019 and by the FDA in January 2025 for use in combination with fludarabine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsPrulifloxacin
go.drugbank.com/drugs/DB11892InvestigationalPrulifloxacin has been investigated for the treatment of Urinary Tract Infection.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsIlaprazole
go.drugbank.com/drugs/DB11964InvestigationalIlaprazole has been investigated in Helicobacter Infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates